Monday, June 22

Browsing: CPOST

Survivors

Checkpoint Inhibitor Evidence: EMPOWER and C-POST Trials

By NewsCancerJune 22, 20260

Dr. Park reviews the three FDA-approved checkpoint inhibitors in cSCC: cemiplimab (approved 2018), pembrolizumab (KEYNOTE-629), and cosibelimab, a PD-L1 inhibitor…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Data science: new data strategy hails exciting future – Cancer Research UK

Rewiring the life sciences: why foundations come first for AI in science – Cancer Research UK

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

Browsing: CPOST

Checkpoint Inhibitor Evidence: EMPOWER and C-POST Trials

Data science: new data strategy hails exciting future – Cancer Research UK

Rewiring the life sciences: why foundations come first for AI in science – Cancer Research UK

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

How to Suffer Less When You’re Waiting for Answers

Data science: new data strategy hails exciting future – Cancer Research UK

Rewiring the life sciences: why foundations come first for AI in science – Cancer Research UK

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

How to Suffer Less When You’re Waiting for Answers

Latest Post

Data science: new data strategy hails exciting future – Cancer Research UK

Rewiring the life sciences: why foundations come first for AI in science – Cancer Research UK

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

Subscribe to Updates

What's Hot

Browsing: CPOST